Key Highlights
- Latent Labs exits stealth with $50M total funding, including a $40M Series A co-led by Radical Ventures and Sofinnova Partners.
- Founded by Dr. Simon Kohl, former co-lead of DeepMind’s protein design team and key contributor to AlphaFold2.
- Investors include Google Chief Scientist Jeff Dean, Transformer architecture inventor Aidan Gomez, and ElevenLabs founder Mati Staniszewski.
- Latent Labs’ AI platform enables de novo protein design, expediting drug development and unlocking new therapeutic targets.
- Operates in London and San Francisco, combining AI innovation with in-lab experimental validation.
Source: Business Wire
Notable Quotes
- “Every biotechnology or pharmaceutical company wants to be at the forefront of technology to find the best therapeutic molecules, yet not all are in a position to develop the most advanced AI models for the job. That’s where Latent Labs comes in.” — Dr. Simon Kohl, CEO & Founder at Latent Labs
- “We’ve partnered with Latent Labs because we’re confident that this team will realize the therapeutic and commercial potential of de novo protein design. Such a capability has never before been possible, one which can benefit humanity in such a profound way.” — Aaron Rosenberg, Partner at Radical Ventures
- “Latent Labs transforms biology from an observational science into an engineering craft, granting us precise control over life’s building blocks.” — Edward Kliphuis, Partner at Sofinnova Partners
Why This Matters
Latent Labs is pioneering AI-driven generative biology, a breakthrough technology that allows researchers to design new proteins with therapeutic and industrial applications. By leveraging AI to create custom molecules, the company aims to accelerate drug development, improve treatment success rates, and unlock new avenues for precision medicine. With backing from leading investors and industry veterans, Latent Labs is set to redefine biotechnology and pharmaceutical innovation.
